CPRX
CATALYST PHARMACEUTICALS, INC.
Nasdaq: CPRX · Coral Gables, FL · Healthcare
$25.64-0.43 (-1.65%)Closed
Market Cap$3.14B
Cash$709.2Mmost recent
Runwayprofitable
P/E (TTM)15.3EPS $1.68
52-Wk Range$19.13 – $26.31
Avg Volume1.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$25.64+69.8%
Pipeline
Drug candidates sponsored by CATALYST PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 2 | Vigabatrin | Cocaine Addiction+1 more | Completed | 2012-10past | 2 | |
| Phase 3 | Amifampridine Phosphate | Lambert Eaton Myasthenic Syndrome+8 more | Completed | 2022-08-05past | 7 | |
| Phase 2 | CPP-109 vigabatrin | Methamphetamine Dependence | Terminated | 2009-06past | 1 | |
| Phase 2 | Amifampridine Phosphate 10 MG Oral Tablet | Spinal Muscular Atrophy Type 3 | Terminated | 2021-09-13past | 1 | |
| Phase 1 | CPP-115 | Cocaine Dependency | Completed | 2012-06past | 1 | |
| N/A | Vamorolone | Duchenne Muscular Dystrophy | Recruiting | 2032-02 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for CPRX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.